Royalty Pharma (NASDAQ:RPRX - Get Free Report) had its price target hoisted by stock analysts at TD Cowen from $68.00 to $80.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a "buy" rating on the biopharmaceutical company's stock. TD Cowen's price target points to a potential upside of 16.42% from the company's previous close.
Several other equities analysts have also commented on the stock. JPMorgan Chase & Co. raised their target price on shares of Royalty Pharma from $58.00 to $62.00 and gave the company an "overweight" rating in a report on Friday, August 7th. The Goldman Sachs Group reaffirmed a "buy" rating and set a $66.00 price target on shares of Royalty Pharma in a report on Thursday, August 6th. Weiss Ratings upgraded shares of Royalty Pharma from a "buy (b-)" rating to a "buy (b)" rating in a research report on Monday, September 14th. Citigroup lifted their price objective on shares of Royalty Pharma from $70.00 to $78.00 and gave the company a "buy" rating in a research note on Thursday, November 5th. Finally, Wall Street Zen upgraded shares of Royalty Pharma from a "buy" rating to a "strong-buy" rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus target price of $65.00.
Get Our Latest Analysis on Royalty Pharma
Royalty Pharma Price Performance
Shares of NASDAQ:RPRX traded up $0.04 during trading on Wednesday, reaching $68.72. 158,350 shares of the company traded hands, compared to its average volume of 3,412,188. The firm has a market capitalization of $39.42 billion, a PE ratio of 57.29, a PEG ratio of 1.36 and a beta of 0.37. The company's 50 day moving average is $61.77 and its two-hundred day moving average is $54.81. Royalty Pharma has a 52 week low of $37.31 and a 52 week high of $70.37. The company has a quick ratio of 1.29, a current ratio of 1.29 and a debt-to-equity ratio of 0.77.
Insider Activity at Royalty Pharma
In other news, EVP Christopher Hite sold 100,000 shares of Royalty Pharma stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $58.53, for a total transaction of $5,853,000.00. Following the transaction, the executive vice president owned 270,401 shares in the company, valued at approximately $15,826,570.53. The trade was a 27.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 4,126 shares of Royalty Pharma stock in a transaction on Monday, October 5th. The stock was sold at an average price of $57.10, for a total transaction of $235,594.60. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 108,252 shares of company stock valued at $6,327,407. Corporate insiders own 18.84% of the company's stock.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE raised its holdings in shares of Royalty Pharma by 29.0% during the first quarter. Bank of America Corp DE now owns 3,495,846 shares of the biopharmaceutical company's stock valued at $167,696,000 after purchasing an additional 786,921 shares during the period. Amundi grew its stake in shares of Royalty Pharma by 15.3% in the 1st quarter. Amundi now owns 3,088,773 shares of the biopharmaceutical company's stock valued at $148,168,000 after buying an additional 409,394 shares during the period. Regal Partners Ltd grew its stake in shares of Royalty Pharma by 2.9% in the 3rd quarter. Regal Partners Ltd now owns 2,519,922 shares of the biopharmaceutical company's stock valued at $147,063,000 after buying an additional 72,043 shares during the period. Dorsey Asset Management LLC grew its stake in shares of Royalty Pharma by 0.8% in the 1st quarter. Dorsey Asset Management LLC now owns 2,276,570 shares of the biopharmaceutical company's stock valued at $109,207,000 after buying an additional 17,101 shares during the period. Finally, Swiss National Bank increased its position in Royalty Pharma by 5.8% in the 1st quarter. Swiss National Bank now owns 1,191,100 shares of the biopharmaceutical company's stock valued at $57,137,000 after buying an additional 65,700 shares in the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.
Royalty Pharma Company Profile
(
Get Free Report)
Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding. The company's portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Royalty Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.
While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.